nature portfolio

corresponding author(s):	Keith Siew, Stephen Walsh
Last updated by author(s):	2023/07/19

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

S	ŀа	ti	ict.	ics
\mathcal{I}	ıч	U	50	100

For	all statistical ar	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a	Confirmed			
	The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement		
	A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
	The statis Only comm	tical test(s) used AND whether they are one- or two-sided non tests should be described solely by name; describe more complex techniques in the Methods section.		
	A descript	cion of all covariates tested		
	A descript	ion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
	A full desc	cription of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) tion (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.			
\boxtimes	For Bayes	ian analysis, information on the choice of priors and Markov chain Monte Carlo settings		
\boxtimes	For hierar	chical and complex designs, identification of the appropriate level for tests and full reporting of outcomes		
\boxtimes	Estimates	of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated		
	1	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
So	ftware an	d code		
Poli	cy information	about <u>availability of computer code</u>		
Da	ata collection	N/A		
Da	ata analysis	DESeq2 library (v 1.38.3); R language (v 4.2); bioMart library (v 3.16); (CLC-GW, ver.10.1.1, Qiagen); WGCNA; MIENTURNET; GraphPad Prism 9 (v.9.5.1); Proteome Discoverer (ThermoScientific; v2.5) (PD 2.4); Cytoscape StringApp; MetaboAnalyst 5.0; Whole metaGenome Sequence Assembly pipeline, version 2 (WGSA2); MetaScape; Scalable Precision Medicine Open Knowledge Engine (SPOKE); QuPath (v0.4.3); . Ilastik (v1.4.0); Syglass (v.1.7.2-79); Imaris (v10.0)		

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Data Availability Statement

- Fig 1. A,B) Aggregated from NASA OSDR (https://osdr.nasa.gov/bio/)
- Fig 2. A; Extended Data Fig 1. A,B) only available per comms from NASA (contact Scott Smith) under specific usage conditions and deidentified in order to preserve astronaut anonymity.
- Fig 2. B; Suppl Info 1,2) underlying data from NASA OSDR (https://osdr.nasa.gov/bio/): OSD-462
- Fig 2. C; Fig 3. A,B; Fig 4; Extended Data Fig 2,3,5,6,8; Suppl Info 3,4,8,9) underlying datasets from NASA OSDR (https://osdr.nasa.gov/bio/): OSD-102, 163, 253, 336, 342, 462, 513, 457, 530, 532, // Overbey et al., Nature. In Review. Nature ID: 2022-12-20632: The Space Omics and Medical Atlas (SOMA): A comprehensive data resource and biobank for astronauts // Hourebi et al., Nature Metabolomics. Submitted. NATMETAB-A23069187.: Secretome profiling captures acute changes in oxidative stress, brain homeostasis and coagulation from spaceflight
- Fig 2. D; Extended Data Fig 8; Suppl Info 5,6) underlying datasets from NASA OSDR (https://osdr.nasa.gov/bio/): OSD-72, 212, 249, 250, 465, 466
- Fig 2. E; Extended Data Fig 8; Suppl Info 7) Rat data at request of CNSA authors (https://doi.org/10.3389/fphys.2020.00939) // MHU-3 data at request of JAXA authors (https://ibsls.megabank.tohoku.ac.jp/metabolite-list) // Hourebi et al., Nature Metabolomics. Submitted. NATMETAB-A23069187.: Secretome profiling captures acute changes in oxidative stress, brain homeostasis and coagulation from spaceflight.
- Fig 3. C) data available from Peptide Atlas (https://peptideatlas.org/): PASS00239
- Fig 3. D; Fig 5. B,C; Suppl Info 10,11,12,15) imaging data is available on request to k.siew@ucl.ac.uk. Currently this is not available in a repository due to the extremely large size of the raw image files, and will be made available as soon as these repositories have storage capabilities.
- Fig 5. A; Extended Data Fig. 8,9,) urinary biochemistry data are available on request to k.siew@ucl.ac.uk. Once OSDR is upgraded to support these type of data they will be made publicly available on this repository.
- Fig 5. D; Extended Data Fig. 10; Suppl Info 17) raw 2D spatial transcriptomic data is available on request to k.siew@ucl.ac.uk. Once OSDR is upgraded to support these type of data they will be made publicly available on this repository.

Extended Fig. 1 C; Extended Data Fig. 8) Data available per comms with Mason group // Kim et al. Nature. In Review. Nature ID: 2023-02-01822: Single-cell multiome and immune profiles of the Inspiration4 crew reveal variegated, cell-type, sex-specific differences to spaceflight and recovery.

Extended Data Fig. 4) kidney and bodyweight data are available on request to abehesht@broadinstitute.org for BNL-1/2/3 mice and to valery.boyko@nasa.gov and NASA OSDR (https://osdr.nasa.gov/bio/): OSD-513

Extended Data Fig. 7) qPCR data are available are available on request to schisler@unc.edu.

Suppl Info 13, 14, 16) underlying datasets from NASA OSDR (https://osdr.nasa.gov/bio/): OSD-336

Research involving human participants, their data, or biological material

Policy information about studies with <u>human participants or human data</u>. See also policy information about <u>sex, gender (identity/presentation)</u>, <u>and sexual orientation</u> and <u>race, ethnicity and racism</u>.

Reporting on sex and gender

As indicated in the text (See table 1), the findings apply mostly male humans; due to the crew make up of the human crewed space flight missions. We are not at liberty to disaggregate the sex/gender data due to the onerous conditions of anonymity for the small number of astronauts and ethical concerns around identification.

Reporting on race, ethnicity, or other socially relevant groupings

We have not subclassified or studied different racial or ethnic groups in these studies, due to the onerous conditions of anonymity for the small number of astronauts and the ethical concerns around identification.

Population characteristics

We are unable to provide population characteristics due to the onerous conditions of anonymity for the small number of astronauts and the ethical concerns around identification.

Recruitment

Participants were recruited as part of the selection process for the relevant space missions. The details of which are not accessible to the general public in all instances.

Ethics oversight

All crews from the Inspiration4, NASA, JAXA spaceflights provided informed written consent prior to their participation. More specifics are below:

Inspiration4 subjects were consented at an informed consent briefing (ICB) at SpaceX (Hawthorne, CA), and samples were collected and processed under the approval of the Institutional Review Board (IRB) at Weill Cornell Medicine, under Protocol 21-05023569. All crew members have consented for data and sample sharing. Tissue samples were provided by SpaceX Inspiration4 crew members after consent for research use of the biopsies, swabs, and biological materials. The procedure followed guidelines set by the Health Insurance Portability and Accountability Act (HIPAA) and operated under Institutional Review Board (IRB) approved protocols. Experiments were conducted in accordance with local regulations and with the approval of the IRB at Weill Cornell Medicine (IRB #21-05023569).

NASA IRB (CSA defers to NASA's IRB), ESA IRB, JAXA IRB for their respective crewmembers from Biochemical Profile (NASA IRB Pro0797) and Nutritional Status Assessment: SMO 016E (pro0326) projects. All crews provided informed written consent

	prior to participation.
	The JAXA human spaceflight study was proposed to and supported by the 2014 International Life Sciences Research Announcements, JAXA, and NASA. Ethics committee approvals were obtained at the University of Tsukuba (No. 251, Nov. 27, 2015), JAXA (JX-IRBA-20-071, Aug. 30, 2016), NASA (Pro1995, Feb. 28, 2017), ESA (2017_04_09, Apr. 20, 2017). Informed consent was obtained by the personal information manager of the study, and de-identified samples were made available to researchers who performed sample processing and data analysis.
	Cosmonaut data were obtained from previously published data [https://link.springer.com/article/10.1007/s10517-013-2310-2]
Note that full informat	cion on the approval of the study protocol must also be provided in the manuscript.
Field-spe	cific reporting
Please select the on	e below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
∠ Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of th	ne document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
Life scien	ces study design
All studies must disc	close on these points even when the disclosure is negative.
Sample size	Due to the nature of our study we used samples from animals that had been in spaceflight (usually as part of the 'Rodent Research' missions to the International Space Station) or had been taken from costly experiments using the Galactic Cosmic Radiation Simulator at Brookhaven national laboratories. We also used samples and/or data from humans who had undergone spaceflight (in historical NASA missions, Roscosmos missions, and JAXA missions the ISS or modern commercial missions with SpaceX such as inspiration4). Our sample numbers were therefore limited to the number of samples made available to us in the original experimental designs or mission parameter limitations (restricted by practical considerations of weight to lauch, available space and resource consumption). In all cases, we endeavoured to use the maximum number of biological replicates available to us to maximise experimental power.
Data exclusions	Data were only excluded on technical grounds due to poor sample preservation quality where positive control measures or QC standards failed, or where the identity of samples matching to animals/participant ID number could not be validated and mislabelling was suspected.

Reporting for specific materials, systems and methods

qPCR, morphometry) were reproduced in a minimum of 3 biological replicates.

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

decoding of original experimental groups only done at the end of statistical analysis to reduce the risk of bias.

All -omics studies were performed using a minimum of three technical & three biological replicates. All low-throughput studies (e.g. imaging,

Where feasible to do so, all samples were analysed using a randomised block design for each assay, with a new randomisation applied to each

Where feasible to do so, all sample collections were done in a blinded fashion. Data were assigned coded identifiers for analysis, with

Ma	terials & experimental systems	Methods		
n/a	Involved in the study	/a Involved in tl	ne study	
	Antibodies	ChIP-seq		
\times	Eukaryotic cell lines	Flow cytor	metry	
\boxtimes	Palaeontology and archaeology	MRI-based	d neuroimaging	
	Animals and other organisms			
\times	Clinical data			
\times	Dual use research of concern			
\boxtimes	Plants			

Antibodies

Antibodies used

Replication

Blinding

Randomization

new assay.

Sheep polyclonal IgG Anti-human NCC pT46, pT50, pT55 (which targets the conserved mouse NCC pT44, pT48, pT53) [S908B; MRC-PPU Reagents]

Rabbit polyclonal IgG Anti-Rat total NCC (which cross-reacts with mouse and human total NCC) [AB95302; Abcam but also sold under SPC-402D; StressMarq Biosciences and AB3553; Chemicon(Merck)]

Validation

Both these antibodies have been extensively used in the research communities and validated in both knockdown, overexpression and physiologically stimulated in vitro cellular systems [https://mrcppureagents.dundee.ac.uk/product/71984].

They have also been validated orthogonally by IHC and Western blot in mouse tissues, from models which have inhibition (Gitelman syndrome) or stimulation (Gordon syndrome) of NCC abundance and phosphorylation due to alterations in upstream regulators. As well as by colocalisation with other anti-NCC antibodies targeting different protein regions and also in NCC knockout mouse kidney tissues.

[DOI 10.1002/emmm.200900058] [DOI: 10.1093/hmg/ddv185] [DOI: 10.15252/emmm.201505444]

Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

Laboratory animals

As indicated in the text (See table 1), the strains and species of all animals are reported where these were known. Exact ages were not always available and were obtained from NASA Genelab Open Science Data Repository (see detailed citations for all misisons in the online methods section)

Wild animals

N/A

Reporting on sex

As indicated in the text (See table 1), the findings apply mostly female animals (roughly two thirds of animal missions were female). As we were collecting data from previously conducted experiments we did not have the ability to alter this sex disparity. Only one study had both males and females, which enabled us to perform sex difference analyses for parameters such as blood and urine electrolytes.

Field-collected samples

N/A

Ethics oversight

For all animal data coming from from NASA Genelab Open Science Data Repository (see detailed citations for all misisons in the online methods section) the ethical oversight information and protocol number can be found in the Protocol section (e.g. https://osdr.nasa.gov/bio/repo/data/studies/OSD-102).

For BNL-1/2/3 - Brookhaven National Laboratory IACUC Protocol 506 "miRNA Signature Detection and Countermeasures Against HZE Radiation Exposure for Tissue Degeneration".

For NSRL-22A - All care and procedures were approved by the Institutional Animal Care and Use Committees (IACUC) at BNL and CHOP and were in accordance with the AAALAC and National Institute of Health (NIH) guidelines for the care and use of laboratory animals.

For RR-10 - NASA John F. Kennedy Space Center Institutional Animal Care and Use Committee (IACUC) Research Protocol Review IACUC Protocol #: FLT-20-133 "The Role of CDKN1a/p21 Pathway in Microgravity-Induced Bone Tissue Regenerative Arrest - A Spaceflight Study of Transgenic CDKN1a/p21-Null Mice in Microgravity (SpaceX-21)"

Note that full information on the approval of the study protocol must also be provided in the manuscript.